diabetes

Bill Russell, MD, left, with patient and trial participant Spencer Mannahan and his father, Zach. (photo by Evan Dorian)

Milestone in VUMC-affiliated diabetes screening and research program underscores impact of clinical trials

Screening and clinical trials are further advancing research to develop therapies that delay or prevent the progression to clinical disease in people at risk of developing Type 1 diabetes.

From left are Alvin Powers, MD, Daniel Drucker, MD, and Steven Eskind, MD, associate professor of Surgery, son of Annette and Irwin Eskind. (photo by Donn Jones)

Leading GLP-1 expert shares insights on groundbreaking drugs for glucose control, weight loss

Drucker and his team study the molecular biology and physiology of the GLP-1 and GLP-2 molecules that regulate glucose metabolism, insulin secretion and energy balance.

GLP-1 medicines are focus of Discovery Lecture on Nov. 21

Daniel Drucker, MD, a pioneering scientist whose research contributed to the development of the blockbuster GLP-1 medicines used to treat diabetes and obesity, was listed by TIME magazine as one of the 100 Most Influential People of 2024.

Blockbuster obesity drugs also may slow kidney disease

The report supports previous clinical trials that found the GLP-1 receptor agonist drug semaglutide reduced kidney disease progression in patients with Type 2 diabetes.

Study seeks to improve brain health in children with Type 1 diabetes

Children with Type 1 diabetes are at increased risk for neurocognitive complications. Vanderbilt University Medical Center has been selected as one of 11 clinical centers in the United States to evaluate children newly diagnosed with Type 1 diabetes for neurocognitive outcomes.

(iStock)

New study to explore infection response in diabetes

With a $3 million research grant, Henrique Serezani will investigate how altered metabolism in diabetes affects inflammation and sepsis.

1 2 3 18